Clinical Trial Update: A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

This Phase 1 study evaluating ASTX660 alone and in combination with ASTX727 in relapsed/refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASTX660
• ASTX727 (cedazuridine/decitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED